Spinocerebellar Ataxia
VIDEO: Troriluzole alters trajectory of spinocerebellar ataxia
DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole.
Vico receives $60M funding to support novel therapy for neurodegenerative conditions
A clinical-stage genetic medicine firm has announced $60 million in Series B financing to support a phase 1/2 clinical trial and advance its lead candidate to treat spinocerebellar ataxia types 1 and 3 as well as Huntington’s disease.
First patient dosed in phase 1/2a trial of Huntington’s, spinocerebellar ataxia therapy
Vico Therapeutics announced that the first patient has been dosed in a phase 1/2a study evaluating VO659, an investigational antisense oligonucleotide for Huntington’s disease and spinocerebellar ataxia types 1 and 3.
Riluzole ineffective for treatment of moderate spinocerebellar ataxia type 2
Riluzole did not improve clinical or radiological outcomes in patients with moderate spinocerebellar ataxia type 2, according to study results published in Lancet Neurology.